Vigonvita Life Sciences publishes 2025 annual report

• Vigonvita reported in its annual report for year ended Dec. 31, 2025 that commercialization of erectile dysfunction drug Angweida (TPN171) began in 2025, with first batch delivered in early August following marketing clearance on July 8.
• License-out program for VV116 in respiratory syncytial virus supported revenue growth via milestone receipts, with VV116 dry suspension completing Phase II in 2025 then moving into Phase III following an End-of-Phase 2 meeting in December.
• Simcere Pharmaceutical deal signed in December grants exclusive Greater China rights for VV116 in RSV infection, human metapneumovirus infection, with Vigonvita eligible for upfront payment, milestones, royalties.
• Digital-first go-to-market expanded, with a 22-person digital marketing team formed, flagship stores opened across six major China platforms.
• Pipeline advanced in neuropsychiatry, with LV232 enrolling first Phase II patient in March, with VV913 filed for IND in October then cleared for clinical trials in January 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vigonvita Life Sciences Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260430-12140586), on April 30, 2026, and is solely responsible for the information contained therein.